PTGS2 and colorectal carcinoma: Additionally, nonsteroidal anti-inflammatory drugs (NSAIDs) and the selective COX-2 inhibitor celecoxib have been shown to block CTNNB1-dependent transcription in CRC [41,42,43,44].